Navigation Links
Reportlinker Adds Biomarkers: Technologies and Global Markets
Date:5/3/2011

NEW YORK, May 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarkers: Technologies and Global Markets

http://www.reportlinker.com/p0488647/Biomarkers-Technologies-and-Global-Markets.html

In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate (CAGR) of 19.8%.

Of all segments, genomics will continue as the largest, at 2010 revenue of $5.1 billion, growing to $16.9 billion in 2015, a compound annual growth rate (CAGR) of 26.9%. Genomics has been and will continue to be the fastest-growing driver of biomarker technology.

Imaging, as a modality, completed 2010 with $4.2 billion in revenue. The next 5 years will continue to see growth, slightly outpacing proteomics, at a 14.8% compound annual growth rate (CAGR) from 2010 to 2015 to reach a value of $8.4 million in 2015. 

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for products and services in the biomarkers segment. Individual product-types are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.

The biomarkers market presents the largest of all opportunities in representative disease subsegments. This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets, by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.

SCOPE OF REPORT

Current and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the FDA, and those products expected to be approved within the forecast period are projected. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For all areas, including the very large markets segments such as infectious disease and cardiovascular specific mechanisms of action are discussed in detail.

The report includes analysis of leading and emerging competitors in the current worldwide biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.

Market figures are based on revenues at the manufacturers' level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.

Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the biomarkers market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease subsegment.

Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician's prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the biomarkers market, its products, its industry participants, and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:

Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D. Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their biomarker product or technology as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study. Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis. Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this study. In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.

The overall biomarkers sector is comprised of a variety of fast-growing and independent segments. For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment. Each sub-section contains detailed forecasts for each driving mechanism, or relevant area of growth.

Information to prepare this report was obtained from participating and emerging companies in the biomarkers area; American Heart Association, the National Heart, Lung and Blood Institute and the National Heart, Lung, and Blood Institute; articles published in medical journals such as American Heart Journal, Circulation, Journal of Biomarkers Pharmacology, Lancet, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks; and others. Population estimates are based on those reported by the international data-base of the U.S. Census Bureau.

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

METHODOLOGY AND INFORMATION SOURCES

RELATED REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY TABLE GLOBAL BIOMARKERS FORECAST BY AREA, THROUGH 2015 ($ MILLIONS)

SUMMARY FIGURE GLOBAL BIOMARKERS FORECAST BY AREA, THROUGH 2015 ($ MILLIONS)

CHAPTER THREE: OVERVIEW

INTRODUCTION

TABLE 1 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($ MILLIONS)

ENABLING ADVANCEMENTS DRIVING MARKET GROWTH

BIOMARKERS DRIVE SPEED, COST AND QUALITY IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT SPECTRUM

COST REDUCTION OPPORTUNITIES ARISING FROM BIOMARKER APPLICATIONS

Elements of Cost in Drug Research & Development

FIGURE 1 CUMULATIVE COST OF CLINICAL DRUG DEVELOPMENT

FIGURE 2 AVOIDABLE COST OF $177.4B OF DRUG-RELATED MORBIDITY AND MORTALITY

Elements of Cost in Healthcare

FIGURE 3 VARIANCE ANALYSIS OF INCREASED COST ORIGINATING FROM DRUG-RELATED MORBIDITY AND MORTALITY

STRATEGIC BIOMARKER APPLICATIONS

Targeted Therapies

Product Extensions

Ultra-Blockbuster

DRUG DEVELOPMENT USING BIOMARKERS: MARKET ENTRY THEORY AND IMPLICATIONS

FIGURE 4 DECISION TREE AND ECONOMICS FOR BIOMARKERS AT POINT OF CARE

Breakeven Analysis of Diagnostic-Enabled Drug Model

FIGURE 5 PRICE, COST, ADOPTION PERCENT FOR BIOMARKER ENVIRONMENT

FIGURE 6 BREAKEVEN LEVEL FOR ADOPTION OF BIOMARKER

Implications for Industry

BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT

Safety/toxicology Biomarkers

TABLE 2 NOVEL SAFETY / TOXICOLOGY BIOMARKERS USED IN CANCER, CARDIO AND RENAL

Dose Selection and Dose Optimization

TABLE 3 NOVEL DOSE SELECTION BIOMARKERS USED IN CANCER, DIABETES, METABOLIC AND LIVER DISEASE

Improved Measurement of Therapeutic Efficacy

Outcome Biomarkers and Surrogate Endpoints

TABLE 4 PATIENT OUTCOME MEASUREMENTS BIOMARKERS

EARLY-STAGE CLINICAL TRIAL APPLICATIONS

LATE-STAGE CLINICAL TRIAL APPLICATIONS

Phase III

Phase IV

BIOMARKERS: CHALLENGES AND OPPORTUNITIES

SUMMARY

CLINICAL VALIDITY: REQUIREMENTS

BIOMARKER OPPORTUNITIES

PRODUCT SUMMARY AND MARKET

GENOMICS

TABLE 5 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($ MILLIONS)

IMAGING

PROTEOMICS

BIOINFORMATICS

OTHER

Metabolomics

BIOMARKER ADOPTION BY THE PHARMACEUTICAL INDUSTRY

GROWTH DRIVERS AND RESISTORS

FACTORS INFLUENCING BIOMARKER ADOPTION IN CLINICAL TRIALS

CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE

IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL TRIALS

Merck: Vicriviroc

Myriad: Flurizan

ADDITIONAL CAPABILITIES BY LARGE SERVICE PLAYERS

TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND PROTEOMICS

BIOMARKER MARKET FORECAST

TABLE 6 GLOBAL BIOMARKER MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

CHAPTER FOUR: REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS

INTRODUCTION

ROLE OF THE FOOD AND DRUG ADMINISTRATION

TABLE 7 FDA GUIDELINES FOR BIOMARKER APPLICATIONS

EUROPEAN MEDICINES AGENCY

REGULATORY IMPACT ON DRUG SAFETY

INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING

APPROVED PATENT ANALYSIS

TABLE 8 ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN U.S., EUROPE, JAPAN, THROUGH 2010

COMPETITIVE LANDSCAPE

LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING

TABLE 9 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2010 ($ MILLIONS)

TABLE 10 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY

TABLE 11 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN U.S., EUROPE, JAPAN

ETHICAL CONSIDERATIONS

SUMMARY

Respect for Persons

Beneficence

Justice

BIOMARKER APPLICATIONS OF ETHICAL CONSIDERATIONS

Race and Genotype

Negligence

Informed Consent

Privacy

Market Segmentation

Professional, Media, and Opinion Leader Edification

REGULATORY IMPLICATIONS

CHAPTER FIVE: APPLICATION BY THERAPY AREA

TABLE 12 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY THERAPEUTIC AREA, THROUGH 2010 ($ MILLIONS)

ONCOLOGY

TABLE 13 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY

COLORECTAL CANCER

CETUXIMAB

PANITUMUMAB

ELESCLOMOL

HERCEPTIN

OTHER PREDICTIVE TESTS

TABLE 14 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY

BREAST CANCER

MAMMAPRINT

TABLE 15 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER

ONCOTYPE DX

TEST ADOPTION

OTHER PROGNOSTIC TESTS

PREDICTIVE TESTS

HORMONAL THERAPIES

TAXANES/ANTHRACYCLINES

BIOLOGICALS

TRIPLE NEGATIVE BREAST CANCER

OTHER NOVEL BIOMARKERS

LUNG CANCER

INTRODUCTION

PREDICTIVE TESTS

TABLE 16 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER

GEFITINIB

ERLOTINIB

OTHER PREDICTIVE TESTS

NOVEL THERAPIES

OTHER ONCOLOGY

PROSTATE CANCER

OVARIAN CANCER

MALIGNANT MELANOMA

TABLE 17 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA

OTHER DISEASES

CARDIOVASCULAR

TABLE 18 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: CARDIOVASCULAR

TABLE 19 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR

CENTRAL NERVOUS SYSTEM

TABLE 20 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE

TABLE 21 CLINICAL BIOMARKERS IN CYP2D6 FAMILY FOR CNS DISEASE

IMMUNOLOGY

TABLE 22 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY

Immunology: Benlysta: Human Genome Sciences

Expedition & Identity Alzheimer's trial: Eli Lilly

CLINICAL BIOMARKERS: THERAPEUTIC DISEASE MARKET FORECAST

TABLE 23 GLOBAL MARKET FORECAST FOR CLINICAL STAGE BIOMARKERS, THROUGH 2015 ($ MILLIONS)

TABLE 24 2015 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2015 ($ MILLIONS)

TABLE 25 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATE STAGE CLINICAL USE BY REGION, THROUGH 2015 ($ MILLIONS)

CHAPTER SIX: BIOMARKERS ACTIVELY GUIDING DRUG DEVELOPMENT

INTRODUCTION

TABLE 26 RECENT CORPORATE ALLIANCES BETWEEN BIOMARKER AND DRUG DEVELOPMENT COMPANIES

ASURAGEN

BACKGROUND

COLLABORATION: MERCK & CO.

BG MEDICINE

BACKGROUND

COLLABORATION: CORDEX PHARMA

BIOMÉRIEUX

BACKGROUND

COLLABORATIONS: ISPEN; MERCK & CO.

Ipsen

Merck & Co.

ADNA PROJECT

CELERA

BACKGROUND

COLLABORATIONS

Abbott

Merck & Co

Ipsen

CURIDIUM

BACKGROUND

COLLABORATION: TAKEDA

DAKO

BACKGROUND

COLLABORATION: OSI

OSI Pharmaceuticals

Genentech

Bristol-Myers Squibb

DXS

BACKGROUND

COLLABORATIONS

Amgen

Roche Molecular Diagnostics

GE HEALTHCARE

BACKGROUND

COLLABORATION: ELI LILLY

GENOMIC HEALTH

BACKGROUND

COLLABORATIONS

Pfizer

Bristol-Myers Squibb and Imclone Systems

HISTORX

BACKGROUND

COLLABORATION: LILLY

LILLY

LABCORP

BACKGROUND

COLLABORATION

ARCA Biopharma

Vanda Pharmaceuticals

Medco Health Solutions

MONOGRAM BIOSCIENCES

BACKGROUND

COLLABORATIONS

Pfizer HIV Partnership

VeraTag Oncology Platform

ONCOMETHYLOME SCIENCES

BACKGROUND

COLLABORATIONS

Merck KGaA

Schering-Plough

GlaxoSmithKline Biologicals

Abbott


'/>"/>
SOURCE MDX
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
2. Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
3. Reportlinker Adds R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment
4. Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips
5. Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes
6. Reportlinker Adds China Bio-breeding Industry Report, 2010
7. Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other
8. Reportlinker Adds Biomarker Partnering Terms and Agreements
9. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
10. Reportlinker Adds Industrial Biotechnology China News 1103
11. Reportlinker Adds DNA Sequencing - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- On Thursday, February 11, 2-1-1 San Diego ... and disaster services, and the Community Information Exchange ... coordination and service delivery for the community to better ... better connect service providers to the information they can ... has handled more than 2.5 million connections ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/27/2016)... Jan. 27, 2016  Rite Track, Inc. a leading ... West Chester, Ohio announced today the ... staff, based in Austin, Texas , ... to provide modifications, installations and technical support offerings for ... of PLUS, commented, "PLUS has provided world class service ...
Breaking Biology News(10 mins):